Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials

A Sahebkar, LE Simental-Mendia, Ž Reiner… - Pharmacological …, 2017 - Elsevier
Orlistat, an inhibitor of intestinal lipase, promotes body weight reduction. The lipid-lowering
efficacy of orlistat is controversial and the effect of orlistat-induced body weight reduction on …

The human paraoxonase gene cluster as a target in the treatment of atherosclerosis

ZG She, HZ Chen, Y Yan, H Li, DP Liu - Antioxidants & redox …, 2012 - liebertpub.com
The paraoxonase (PON) gene cluster contains three adjacent gene members, PON1, PON2,
and PON3. Originating from the same fungus lactonase precursor, all of the three PON …

[HTML][HTML] Anti-atherogenic effects of orlistat on obesity-induced vascular oxidative stress rat model

ZA Othman, Z Zakaria, JB Suleiman, WSW Ghazali… - Antioxidants, 2021 - mdpi.com
Obesity is typically linked to oxidative stress and inflammation, which lead to vascular
damage and initiate the progression of atherosclerosis. The aim of this study was to …

[HTML][HTML] Modulatory effect of lifestyle-related, environmental and genetic factors on paraoxonase-1 activity: a review

D Kunachowicz, M Ściskalska, M Kepinska - International Journal of …, 2023 - mdpi.com
Paraoxonase-1 (PON1) is a calcium-dependent, HDL-bound serum hydrolase active toward
a wide variety of substrates. PON1 displays three types of activities, among which lactonase …

[HTML][HTML] Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia

SK Kota, LK Meher, SK Kota, S Jammula… - Indian journal of …, 2013 - journals.lww.com
Abstract Human serum paraoxonase 1 (PON1) is an enzyme with esterase activity, and is
physically bound to high-density lipoproteins (HDL). It plays a key role in the action of HDL …

Orlistat: current status in clinical therapeutics

KS McClendon, DM Riche, GI Uwaifo - Expert opinion on drug …, 2009 - Taylor & Francis
Background: Obesity has rapidly become a life-threatening epidemic worldwide. There are a
plethora of obesity-related co-morbidities and complications that increase morbidity …

Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation

S Tabur, AN Torun, T Sabuncu… - European journal of …, 2010 - academic.oup.com
Abstract Objective Paraoxonase-1 (PON-1), which has PON and arylesterase activities, is a
high-density lipoprotein (HDL)-bound antioxidant enzyme that inhibits atherosclerosis …

[HTML][HTML] Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels

P Koncsos, I Seres, M Harangi, I Illyés, L Józsa… - Pediatric …, 2010 - nature.com
Childhood obesity is a predisposing factor for adult cardiovascular diseases. Human serum
paraoxonase (PON1) may protect against atherosclerosis by hydrolyzing lipid peroxides in …

The growing importance of PON1 in cardiovascular health: a review

M Macharia, MS Hassan, D Blackhurst… - Journal of …, 2012 - journals.lww.com
The wide acceptance of the oxidation theory of atherogenesis has prompted attention to
antioxidant mechanisms, particularly the prevention of lipid oxidation by high-density …

[HTML][HTML] Relationship between the paraoxonase (PON1) L55M and Q192R polymorphisms and obesity in a Mexican population: a pilot study

MF Martínez-Salazar, D Almenares-López… - Genes & nutrition, 2011 - Springer
The aim of this study was to examine the relationship between the L55M and Q192R
paraoxonase (PON1) polymorphisms and obesity in a population of adult Mexican workers …